{
    "nctId": "NCT00308178",
    "briefTitle": "Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer",
    "officialTitle": "Dose Dense AB1-007 (Abraxane) in Adjuvant Chemotherapy for Breast Cancer: A Feasibility Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 66,
    "primaryOutcomeMeasure": "To evaluate the feasibility and toxicity of Abraxane after chemotherapy as part of dose-dense adjuvant chemotherapy for breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast cancer, with clinical stage I, II, or III disease\n* Must register at the beginning of adjuvant or neoadjuvant chemotherapy\n* 18 years of age or older\n* ECOG performance status of 0 or 1\n* Normal organ and marrow function\n\nExclusion Criteria:\n\n* Previous cytotoxic chemotherapy or therapeutic radiation therapy for any reason\n* Pregnant or nursing\n* Receiving any other investigational agents\n* Patients with Stage IV breast cancer\n* Current grade II or greater peripheral neuropathy or prior history of grade II or greater neuropathy\n* Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Immune deficiency when treated with marrow-suppressive therapy or HIV-positive patients receiving anti-retroviral therapy\n* Patients with sickle cell disease\n* Known history of hyperviscosity syndrome\n* Patients on lithium",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}